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Abstract
Tuberculosis (TB) continues to be a major health hazard worldwide due to 
the resurgence of drug discovery strains of Mycobacterium tuberculosis (Mtb) and 
co-infection. For decades drug discovery has concentrated on identifying ligands 
for ~10 Mtb targets, hence most of the identified essential proteins are not utilised 
in TB chemotherapy. Here computational techniques were used to identify ligands 
for the orphan Mtb proteins. These range from ligand-based and structure-based 
virtual screening modelling the proteome of the bacterium. Identification of 
ligands for most of the Mtb proteins will provide novel TB drugs and targets and 
hence address drug resistance, toxicity and the duration of TB treatment.
Keywords: Mycobacterium tuberculosis, target deorphaning, target deconvolution, 
proteome modelling, virtual screening
1. Introduction
Tuberculosis (TB) continues to be a major public health concern with over 
2 billion people currently infected, 8.6 million new cases per year, and more than 
1.3 million deaths annually [1]. The current drug-regimen combination for drug 
sensitive TB consists of isoniazid, rifampicin, ethambutol and pyrazinamide, 
administered over 6 months [2]. If this treatment fails, second-line drugs are used, 
such as para-aminosalicylate (PAS) and fluoroquinolones, which are usually either 
less effective or more toxic with serious side effects. Although this regimen has a 
high success rate, it is marred by compliance issues, which have resulted in the rise 
of multidrug resistant (MDR), extensively drug resistant (XDR) and totally drug 
resistant (TDR) strains of the causative agent, Mycobacterium tuberculosis (Mtb) 
[3, 4], in both immunocompetent and immunocompromised patients worldwide 
[5]. However, it took about 40 years for a new TB drug to be discovered and most 
of the current TB drugs target a total of only ~10 proteins, even though the com-
plete genome of Mtb was published nearly 20 years ago [6]. Consequently, most 
of the essential proteins are orphans since their ligands are still to be identified. In 
our context, target deorphaning or deconvolution encompasses identification of 
ligands for Mtb proteins not currently exploited in TB chemotherapy and those of 
old TB targets. Targeting further essential proteins should allow the fight against 
drug resistance to be enhanced, and possibly lead to a reduction in the duration of 
TB treatment.
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The conventional target deorphaning process involves experimental work, 
which characteristically includes genetic, proteomics and transcriptional profiling 
and then identification of the ligands for the proteins using many more chemical-
proteomic approaches [7]. This approach is usually long, expensive and time 
consuming. However, developments in bioinformatics and chemoinformatics, 
together with advances in computer tools and resources, have fortunately revolu-
tionised target deorphaning. Bioinformatics describes the target space in Mtb from 
the genome to the proteome, whilst chemoinformatics provides information about 
the available chemical space and tools for navigation of the space. Together these 
developments have led to a mushrooming of computer-based target deorphaning 
methods ranging from modelling proteomes, virtual screening, machine and deep 
learning, and chemogenomics [8–10]. When used effectively in conjunction with 
experimental work, computational methods can facilitate identification of new TB 
targets and drugs [11–13].
Therefore, in this chapter we present an overview of the genome of Mtb, giving a 
detailed account on how the computational techniques have been used to de-orphan 
Mtb targets including case studies, the current and proposed future impacts of these 
techniques on the number of de-orphaned Mtb targets and their impacts in boosting 
the biomedical efficacy of TB drugs. The collated data will provide researchers in 
academia and industry with knowledge of target-ligand pairs and interactions, infor-
mation crucial for the design of novel drugs with known targets that are less prone to 
resistance, with minimal side effects and interactions with e.g. anti-HIV drugs.
2. Method
An extensive literature search was performed to give an overview of the genome of 
the Mtb and status of the currently used tuberculosis drugs and their targets. An analy-
sis of the essential proteins in Mtb and the number of proteins targeted by the current 
TB drugs was performed. To boost this data Mtb target-ligand data was extracted from 
the ChEMBL database version 24 (https://www.ebi.ac.uk/chembl/beta/g/#browse/
targets), which was used to determine the number of the proposed new targets. 
An overview of computational deorphaning of Mtb targets is provided, using data 
extracted from literature and a description of the efforts made from our laboratory. 
To sum this up, a detailed account of modelling the proteome for Mycobacteria, and 
identification of the hotspots and druggability of the proteins is given.
3. Genome sequence of Mycobacterium tuberculosis
Cole and co-workers [14] in 1998 reported the complete sequence of Mtb, which 
comprises of 4,411,529 base pairs. The genome has an evenly distributed guanine-
cysteine content of 65.6% and represents the second-largest bacterial genome 
sequence currently available. Additionally, the genome is rich in repetitive DNA, 
particularly insertion sequences, and in new multi-gene families and duplicated 
housekeeping genes, providing evidence for horizontally-transferred pathogenicity 
islands of a particular base composition [14].
The genome of Mtb has some exceptional features, for example there are over 
200 genes that encode enzymes for the metabolism of fatty acids, comprising 6% of 
the total (Table 1). Among these, about 100 are predicted to function in the oxida-
tion of fatty acids. This large number of Mtb enzymes that putatively have fatty 
acids as substrates may be linked to the ability of this pathogen to grow in the tissues 
of the infected host, where fatty acids maybe the major carbon source. Another 
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unusual feature of the Mtb genome is the presence of the unrelated Pro-Glu (PE) 
and Pro-Pro-Glu (PPE) families of proteins that have conserved N-terminal 
domains of 100 and 180 amino acids respectively. The antigenicity of these proteins 
has led to the assumption that at least some of these proteins may be involved in 
antigenic variation of Mtb during infection [15].
3.1 Current status of tuberculosis drugs and targets
3.1.1 Tuberculosis drugs
The success of TB chemotherapy derives from an “intensive” phase involving 
a cocktail of four first-line drugs, comprising, rifampicin (RIF), isoniazid (INH), 
pyrazinamide (PZA), and ethambutol (EMB). A threatening global issue of this 
epidemic is the emergence of drug-resistant bacteria, a trend that is on the rise, as 
such strains are easily spread with low fitness costs associated with transmission 
[16]. The World Health Organisation (WHO) reported that globally 3.5% of naive 
infections already expressed resistance to the two most efficacious frontline agents 
used to treat the disease, RIF and INH, thereby classifying the infection as multi-
drug resistant tuberculosis (MDR-TB) [17]. Treatment of drug-resistant Mtb is dif-
ficult already, requiring 6–9 months of combination therapy of second-line drugs, 
such as PAS, fluoroquinolones e.g. levofloxacin, and aminoglycosides e.g. kanamy-
cin, capreomycin, ethionamide and cycloserine. Complicating the issue is the fact 
that TB is endemic to the developing world; thus, access to adequate healthcare 
facilities and drugs can be limited for those patients. This leads to non-compliance 
by most patients, relapse of the disease and severe side-effects especially of second-
line drugs [18]. Treatment for MDR-TB can extend upwards of 2 years and relies on 
more toxic, less efficacious second-line drugs, many of which are even more scarce 
than frontline drugs in affected areas [16].
In addition, comorbidity with HIV causes massive diagnostic and therapeutic 
challenges and results in adverse drug interactions [19]. This is because RIF is 
a potent inducer of drug-metabolising enzymes, including cytochrome P450 
(CYP) 3A4. This induction dramatically reduces plasma levels of several highly 
active antiretroviral therapy drugs; thus, patients are often forced to complete 
Function No. of 
genes
% of total 
genes
% of total coding 
capacity
Lipid metabolism 225 5.7 9.3
Information pathways 207 5.2 6.1
Cell wall and cell processes 517 13.0 13.5
Stable RNAs 50 1.3 0.2
IS elements and bacteriophages 137 3.4 2.5
PE and PPE Proteins 167 4.2 7.1
Intermediary metabolism and respiration 877 22.0 24.6
Regulatory proteins 188 4.7 4.0
Virulence, detoxification and adaptation 91 2.3 2.4
Conserved hypothetical function 911 22.9 18.4
Proteins of unknown function 607 15.3 9.9
Table 1. 
General classification of Mtb genes. Adopted from [15].
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their TB treatment before beginning HIV treatment [20]. Patients who contract 
MDR-TB with HIV have a very poor prognosis due to the duration of treatment; 
these individuals frequently succumb within a few months. Therefore, there is an 
urgent need to develop continually new active agents to combat MDR-TB which has 
been compounded by the emergence of XDR-TB. Furthermore, cases of TDR-TB 
have been noted in China, India, Africa, and Eastern Europe. In TDR-TB, the 
Mycobacterium are resistant to all available therapeutics [19]. To address this, in 
2012 the U.S. Food and Drug Agency (FDA) approved bedaquiline for MDR-TB [21] 
and later delamanid was approved as a compassionate care option for XDR-TB and 
TDR-TB infections, nonetheless the EMA approved both agents for MDR-TB [22]. 
The biggest challenge is that these drugs have reported human ether-a-go-go related 
gene (hERG) toxicity, as well as multiple absorption, distribution, metabolism and 
excretion (ADME) issues due to their high lipophilicity [21]. This leads to an urgent 
need for development of new agents that have successful therapeutic effects.
3.1.2 Mycobacterium tuberculosis drug targets
To date the number of essential Mtb proteins encoded by approximately 4000 
genes is just over 500 (Figure 1), and this provides a rich source for novel targets 
for new and current TB drugs. However, Lamichhane et al. [23] reported that TB 
chemotherapy exploited only 10 of these proteins; Table 2, gives a summary of 
the targets, and their current and/or new drug ligands. The most popular target is 
enoyl[acyl-carrier protein] reductase, important for the biosynthesis of mycolic acid. 
Efforts to identify genes that code for new potential drugs are underway, as evidenced 
by 76 TB data points recorded in the ChEMBL database version 24 (https://www.ebi.
ac.uk/chembl/beta/g/#browse/targets), consisting of small bioactive compounds, 
their targets and bioassay data. There are 73 single proteins, including the 10 proteins 
already targeted by both first-line and second-line drugs during TB chemotherapy. 
Thus, 63 new drug targets are being explored in a plethora of bioassays.
This is of paramount importance because Mtb secreted proteins play a vital 
role in host-pathogen interactions and facilitate nutrient acquisition, pilot the host 
immune response and interfere with therapeutic intervention. Therefore, the Mtb 
secretome consists of proteins essential for successful invasion and in vivo growth 
during host infection. The essential proteins are the most suitable drug targets for 
the development of diagnostic tools and new drugs, because of their key role in in 
vivo bacterial survival and growth. Identifying ligands for these proteins required 
for growth and survival in the infected host could lead to the discovery of poten-
tially useful biomarkers to add on the above mentioned drug targets [27].
Figure 1. 
Circular diagram of the genome of Mtb genes, essential proteins and the number of proteins that are drug 
targets.
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Targets Function Conventional 
drugs
New ligands
Enoyl-(acyl-carrier-
protein) reductase (InhA), 
Fatty acid synthase
Biosynthesis of mycolic 
acids, that is essential 
for growth and 
virulence
Isoniazid
Ethambutol
Pyrazinamide
Delamanid
Tetrahydropyrans 
(PT070)
Methylthiazoles
Diazaborines
Pyrrolidine-carboxamide
Piperazine 
indoleformamides
Aminoproline
Arylamides
Imidazopiperidines
DNA gyrase An ATP-dependent 
enzyme that acts by 
creating a transient 
double-stranded DNA 
break
Fluoroquinolones Clinafloxacin
Ubiquinol-cytochrome 
C-reductase (QCrB)
Electron carriers of the 
respiratory chain
Pyrrolo[3,4-c]pyridine-
1,3(2H)diones
Lansoprazole
Transmembrane transport 
protein large (MmpL3)
Responsible for heme 
uptake into the cell.
Responsible for the 
transport of ions, 
drugs, fatty acids and 
bile salts
SQ109
Adamantyl ureas
Phenylpyrroles
Benzimidazoles
Tetrahydropyrazolo 
[1,5-a]pyrimidine-3-
carboxamide
Spiropiperidines
Decaprenylphospo-β-D-
ribofuranose-2-oxidase 
(DprE1)
Cell wall synthesis Benzothiazinones 
(BTZ043)
Benzothiazole (TCA1)
4-aminoquinolone 
piperidine amides
2-carboxyquinoxalines
Oxadiazoles
Benzo [b]thiophenes
Pyrazolopyridones
RNA polymerase Responsible for 
transcription
Rifampicin
Rifapentine
Rifabutin
Protein synthase Protein synthesis Linezolid 
(https://www.
drugbank.ca/
drugs/DB00601)
PNU100480
AZD5847
ATP Synthase ATP synthesis Bedaquiline D-Dethiobiotin
Cytidine triphosphate 
(CTP) synthetase
Catalysis of amination 
of uridine triphosphate 
(UTP) into CTP
Thiophenecarboxamide
4-(pyridine 2-yl) thiazole
Transcription factor 
(IdeR)
Regulating the 
intracellular levels of 
iron
Benzo-thiazol benzene 
sulfonic acid
Lysine-ε-amino 
transferase (LAT)
Catalysing reversibly 
the transamination 
of lysine into 
α-ketoglutaric acid
Benzothiazole
Table 2. 
Mtb drug targets and the current used drugs [24–26].
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4. Computer resources and tools for tuberculosis drug targets
The development in genomics, coupled with advances in high performance 
computing and validation of molecular targets, has introduced new approaches 
to drug discovery that provide a shift from the historical pipeline that focuses on 
target identification and in most cases involves single targets. In this era of extensive 
discovery of new chemical entities for treatment of TB and other infectious diseases 
like HIV/AIDs, a number of research institutes as well as pharmaceutical companies 
are eagerly developing computational tools and protocols to facilitate drug discovery 
and development [28]. Genomics provide DNA, RNA, transcriptomic and proteomic 
data that is housed in a variety of databases and provide resources e.g. from the 
European Bioinformatics Institute (EBI) https://www.ebi.ac.uk/, and the National 
Centre for Biotechnology Information (NCBI) https://www.ncbi.nlm.nih.gov/, 
which can be easily retrieved and analysed, thereby shifting the drug discovery focus 
from a single to a multi-protein target approach. In this approach Mtb genomic data 
are analysed for network, structure and function of a number of essential proteins 
that are druggable and validated as potential targets for a number of bactericidal or 
bacteriostatic chemical compounds. In this section, different databases, resources 
and tools for target deorphaning are discussed with a particular focus on Mtb targets.
The revolution in genomics led to the availability of a number of mycobacterial 
genomes and the development of a variety of databases consisting of Mtb genomic 
and transcriptomic data. The genomic databases provide information about the 
structure, function and evolution of Mtb genes, whilst the transcriptomics provide 
information crucial for analysis of gene expression using large scale RNA sequences 
[29]. On the other hand proteomics provides information about the function, 
networks and structure of proteins. In their paper, Machado et al. [29] give a detailed 
summary of most computational resources for TB and we encourage readers to con-
sult the article for more information. Similarly a number of chemogenomic resources 
and database containing data for Mtb ligand annotated targets have been developed. 
Examples of such databases include the ChEMBL database [30], a database of small 
bioactive molecules and their targets, TIBLE [31] a database containing MIC and tar-
get data for mycobacterial species and TDR targets containing target-ligand informa-
tion for neglected tropical diseases including TB. The databases are freely available 
and provide easy access to target-ligand data for Mtb. In these databases each target is 
associated to ligand(s) obtained from bioassays and vice versa.
5. Computational target deorphaning techniques
A number of computational methods are being explored in order to identify 
ligands for both host and pathogen targets and for targets from other organ-
isms like Plasmodium falciparum [32]. In most cases two or more complementary 
ligand-based and structure-based deorphaning approaches are used; statistical 
methods involving machine learning [8] and deep learning strategies are applied in 
conjunction with biological and/or biophysical methods to validate the computa-
tional results or the computational methods are used to provide the protein-ligand 
binding information in the absence of X-ray co-crystallised structures of the ligand 
[12, 13]. In their work, Mendes and Blundell [13] applied cheminformatics to 
complement current efforts for target identification of fragment-sized molecules 
that target e.g. the PanC that synthesises pantothenate important for generation of 
the Mtb co-enzyme A. This has led to the identification of ‘hotspots’ in the binding 
pockets of a number of proteins, which highlight the most favoured binding spots 
for the protein. Hotspots and druggability will be discussed in detail in Section 6.
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5.1 Ligand-based and structure-based virtual screening methods
Structure-based virtual screening is an approach used in drug discovery to com-
putationally screen small molecule databases for compounds that target proteins of 
known 3D structure that are experimentally validated. Brain Shoichet [33] has pointed 
out that this approach was first published in the 1970s, however most new ligands and 
their targets were not identified until the early 2000. The method offers the opportu-
nity to access a large number of potential new chemical ligands for old and new targets. 
In the presence of available ligands for named biological targets, ligand-based virtual 
screening may be used using a variety of techniques ranging from molecular similarity, 
pharmacophoric search, to machine learning and most recently deep learning.
5.1.1 Structure-based techniques
Structure-based virtual screening plays a significant role in drug discovery in 
that it is used to identify ligands for biological targets when the 3D structures of 
the Mtb targets from X-ray crystallography, nuclear magnetic resonance (NMR) 
or cryoelectron microscopy are available in the Protein Data Bank, or homol-
ogy models available in the CHOPIN database and/or generated in house. This 
method applies structural data of proteins/receptors to provide small molecules 
with specific structural attributes for good binding affinity [34]. Generally, the 
process involves three crucial steps, namely preparation of 3D crystal structures 
of proteins obtained from the Protein Data Bank (PDB) and the ligand structures, 
docking calculation and data analysis. Protein structure preparation involves adding 
hydrogen atoms that are normally missing in the coordinate files, adding missing 
residues, optimising hydrogen bonds, removing atomic clashes, as well as sampling 
the degrees of freedom such as flip that are not clear in standard resolution crystal 
structures, for example the 180o flips of chain terminal rotatable side-chain groups 
e.g. in shape-symmetric amino acids Asn and Gln, tautomer and/or ionisation state 
and relaxation of the target and ligand structure [35]. Most docking software is 
associated with protein and ligand preparation tools, for example Autodock4 or 
VINA require structures prepared using AutoDockTools (ADT) and the protein 
preparation script to generate Autodock-type atoms containing Gasteiger charges, 
and produce the pdbqt files that are compatible with the tool [36]. Similarly, the 
Primex and Ligprep tools are used to prepare the protein and ligand structures 
respectively before docking with GLIDE [37]. The quality of input structure files 
contribute to the quality of the docking results, and the importance of protein and 
ligand preparation have been highlighted by Sastry [35].
5.1.1.1 Molecular docking
Molecular docking calculations are capable of predicting the binding conforma-
tion of ligands inside the binding pocket of a target, as such they are used to map 
small molecules onto targets and hence provide essential binding information for 
structure-based drug design. To achieve this, a number of docking algorithms like 
Autodock [36], perform a stochastic conformational search or e.g. in GLIDE, a [37] 
that perform a systematic search [34]. In a stochastic search structural parameters, 
such as torsional, translational and rotational degrees of freedom of the ligand, 
are randomly modified to generate an ensemble of molecular conformations and 
increase the chances of finding the energy global minimum, whilst in a systematic 
conformational search structural features are gradually changed until a local or 
global minimum is reached [34]. During the search, conformations of a number of 
potential binding compounds are explored and evaluated using a specific scoring 
Drug Discovery and Development - New Advances
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function. In addition, the conformations are ranked based on their calculated bind-
ing energy. Highly ranked compounds are selected as ligands for the target. On the 
other hand, reverse or inverse docking is used for identifying targets of drug pheno-
typic hits from a sea of targets. In this way, structure-based screening helps to iden-
tify and explain polypharmacology, molecular mechanism of action of substances, 
facilitate drug repurposing, detect adverse drug reactions and hence toxicity.
5.1.1.2 Deorphaning the HTH transcription regulator, EthR
In an effort to de-orphan the HTH transcription regulator, EthR, and identify 
the binding mode of the ligand, we docked 200 fragment-like compounds from the 
Maybridge database to the highest quality crystal structure of the 23 PDB entries 
using the GOLD algorithm (unpublished work). We used Arpeggio [38], an online 
tool that identifies non-covalent interactions in protein-structures, to assess the role 
of each EthR binding site residue and each small-molecule ligand moiety in con-
tributing to protein-ligand interactions. Visual assessment of interactions involved 
calculating interactions using the Arpeggio web server (http://structure.bioc.cam.
ac.uk/arpeggio) and downloading the results as PyMOL session files, to analyse the 
non-covalent interactions of each residue. We found that in addition to using polar 
contacts, most ligands are stabilised by a cascade of pi-interactions starting from 
Tyr103 close to the entrance of the allosteric pocket to Phe114 located close to the 
HTH-domain and beyond (Figure 2). Furthermore, potential ligands for the protein 
were identified. Information obtained from these results is vital identify ligands with 
a higher probability of binding to EthR, and so improve the potency and safety of 
ethionamide (ETH).
Figure 2. 
(A) Binding modes of two fragment-like molecules inside the long cylindrical allosteric binding pocket of 
EthR defined by five helices. Yellow sticks depict the molecule occupying the upper binding site close to the 
entrance of the pocket and cyan sticks represent a molecule occupying the inner binding site close to the HTH 
domain. (B) EthR-ligand interactions involving Trp103 (yellow) at the entrance of the binding pocket of the 
protein. Ligand atoms and bonds are in pink, grey rings are hydrophobic interactions, red rings show hydrogen 
bonds. (C) EthR-ligand (pink) interactions involving Phe110 located at the center of the binding pocket of 
EthR.
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Similarly, docking calculations were used to assess binding of ligands identified 
from for a novel TB drug target, inosine monophosphate dehydrogenase (IMPDH) 
protein Guab2 that is responsible for the synthesis of xanthosine monophosphate 
(XMP) from IMP, identified from high throughput screening [12]. Hit compounds 
were identified in a single shot high-throughput screen, validated by dose response 
and subjected to further biochemical analysis. The compounds were also assessed 
using molecular docking experiments, providing a platform for their further opti-
misation using medicinal chemistry. From the results, it was observed that occupa-
tion of the nicotinamide sub-site was correlated with interactions of the ligands 
with the purine ring of IMP.
5.1.1.3 Applying concerted computational and experimental approaches
Likewise, we used a combination of ligand-based and structure-based chemoge-
nomic approaches, followed by biophysical and biochemical methods, to identify 
targets for Mtb phenotypic hits deposited in the ChEMBL database [11]. In this 
work, EthR and InhA emerged as potential targets for many of the hits, and some of 
them displayed activity through both targets. From the 35 predicted EthR inhibitors 
25 displayed an inhibition of better than 50%, of which eight showed an IC50 better 
than 50 μM against Mtb EthR and three were confirmed to be also active against 
InhA. Further the EthR-ligand complexes were validated using X-ray crystallogra-
phy in the Blundell laboratory to give new crystal structures which were deposited 
in the Protein Data Bank. These results provide new lead compounds that could be 
further developed into highly active ligands of EthR and InhA and enhance treat-
ment of drug-resistant TB.
6. Modelling proteomes for mycobacteria, hotspots and druggability
A comprehensive understanding of the structural proteomes of mycobacteria 
is essential for novel drug discovery and elucidating the roles of mutations in drug 
resistance. Most researchers begin by defining the 3D-structure using X-ray crystal-
lography, NMR or increasingly cryo-EM. For phenotypic screening and under-
standing off-target hits, where the target is not identified, prior knowledge of the 
structures of all gene products in the target organism is helpful. This has stimulated 
the establishment of several consortia in what is usually known as structural 
genomics, but might more appropriately termed “structural proteomics”.
6.1 Evolution of structural genomics consortia
The Structural Genomics Consortium (SGC) [39] which has focused on proteins 
of interest to medicine, has impressive achievements, in 2011 defining ~40% of 
the structures of proteins from human parasites deposited in the PDB [40]. The 
Tuberculosis Structural Genomics Consortium (TBSGC), an international col-
laboration involving 53 countries, has focused on 3D structures of Mtb [40]. This 
activity and others working on Mtb proteomes have deposited 2274 structures in 
the PDB, but still representing less than 583 gene products, only 13.97% of genome. 
Although this is a small percentage, it compares impressively with knowledge 
of protein structures of two other mycobacterial pathogens where there is great 
clinical interest: for M. leprae causing leprosy there are experimentally-defined 3D 
structures for 15 gene products and for M. abscessus, a free living Mycobacterium, 
which is a growing challenge for cystic fibrosis patients, there are 53 experimen-
tally-defined 3D structures in the PDB.
Drug Discovery and Development - New Advances
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6.2 Comparative 3D modelling of proteins
Comparative modelling proteins, based on the fold recognition and structural 
alignment with the closest homologues that have experimentally solved structures, 
began using interactive graphics in the 1970s [41–43]. The development of auto-
mated modelling software began in the 1980s, initially with Composer [44] and 
later developed with Comparer [45] and Modeller [46], based on satisfaction of 3D 
restraints derived from structurally aligned homologues. Modeller has now been 
cited ~10,500 times in the literature!
6.2.1 Computational modelling pipelines and structural proteome databases
Rapid progress in this and other related software coupled with increasing com-
puting power has enabled genome scale prediction of protein structures, as a viable 
alternative to experimental determination. In order to construct computational models 
of all gene products, which we here refer to as the structural proteome, we identify 
templates by a sequence-structure homology search using Fugue [47], which uses 
local-structural-environment-specific substitution tables to predict the likelihood of a 
common 3D structure. We have incorporated Fugue into a pipeline (Vivace), in which 
templates are selected from TOCCATA (Ochoa Montaño and Blundell, unpublished), 
a database of consensus profiles built from CATH 3.5 [48] and SCOP 1.75A [49] based 
classification of proteins structures (PDB files). PDBs within each profile are clustered 
based on sequence similarity using CD-HIT [50] and structures are aligned using 
BATON, a modified version of COMPARER [45]. After further optimization of the 
clusters by discarding templates with more than 20% difference in sequence identity to 
the maximum hit, remaining templates are classified into states based on ligand binding 
and oligomerization. Five different states, known as “liganded-monomeric,” “liganded-
complexed,” “apo-monomeric,” “apo-complexed” and “any,” are generated in each 
profile hit. Models are built in each of these states using Modeller 9.10 [46] and refined. 
Later NDOPE, GA341 [51] Molprobity [52] and SSAG [53] are used to determine the 
quality of the models.
6.2.2 Mycobacterial proteome databases
The first application of this approach was to construct the Chopin Database  
(http://mordred.bioc.cam.ac.uk/chopin/about), a database of protein structures for 
H37Rv strain of Mtb. This has provided structures that are reasonably certain for around 
65% of gene products. These have proved reliable indicators of the overall structures but 
may have some uncertainties especially in loop regions and domain-domain relation-
ships. A further ~19% probably have correct folds while the remaining would unlikely 
to be correct. Nevertheless, compared to those structures defined experimentally by 
X-ray analysis, this represents a 6-fold increase of structural information available that 
might be useful in assessing druggability and the impacts of mutations.
Similar models of the structural proteome for M. abscessus (Skwark et al., 
unpublished) and M. leprae (Vedithi et al., unpublished) have been developed in 
the group. In M. leprae, of the 1615 gene products, templates were identified for 
1429 gene products and we were able to model 1161 proteins with high confidence. 
A total of 36,408 models were built in different ligand bound and oligomeric states 
for the 1161 proteins. The distribution of Fugue Z score across models indicates 
that only 4% of the proteome has no hits and 15% has poor scores. ~80% of the 
proteome has acceptable and good hits, and the corresponding Z scores. Around 
47% of the protein queries identified templates with identity and coverage greater 
than 40 and 67% of the models in the proteome are of best quality as estimated by 
NDOPE, GA341, Molprobity and Secondary Structure Agreement (SSAG).
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6.2.3 Oligomeric protein models
Current work on structural proteomes includes efforts to extend the modelling 
pipeline to homo-oligomeric (and eventually hetero-oligomeric) structures using com-
parative approaches (Malhotra et al., unpublished), extending models and improving 
models of small molecule complexes, and linking individual protein structures into 
the metabolic networks and interactions in the cell (Bannerman et al., unpublished). 
An example of an oligomeric structure is CTP-synthase, encoded by PyrG, which is 
an essential gene in Mtb identified by transposon saturation mutagenesis [54] and 
catalyses ATP-dependent amination of UTP to CTP with either L-glutamine or ammo-
nia. The allosteric effector GTP functions by stabilising the protein conformation that 
binds to the tetrahedral intermediates formed during glutamine hydrolysis. Its closest 
homologue in M. leprae ML1363 is a target of choice and was modelled using Vivace 
during the proteome modelling exercise. We modelled the apomeric and ligand bound 
states of the model and oligomerized the protomer using our inhouse oligomerization 
pipeline. The protomeric and oligomeric states are depicted in Figure 3A and B.
The models were built by using templates PDB-IDs: 4zdI and 4zdK for PyrG 
of Mtb [55]. Both the templates are 89% identical and 100% coverage to the query 
sequence. The superposition of the models with the templates indicated a root mean 
square deviation (RMSD) of 0.758.
6.3 Structural implications of mutations
We have also spent time over 2 decades analysing the impacts of mutations 
evident in the increasing wealth of available genome sequences for pathogenic myco-
bacteria and cancers. We originally developed SDM [56] in 1997, a method depend-
ing on statistical analysis of environment-dependent amino-acid substitution tables 
[57, 58]. In 2013 machine learning was introduced with the arrival of Douglas Pires in 
Cambridge, developing first mCSM for stability [59] followed by several “flavours” 
including mCSM-PPI for impacts on protein-protein interactions, mCSM-NA [60] 
for nucleic acid interactions and mCSM-lig for impacts on small-molecule ligand 
interactions useful for understanding drug resistance [61]. A critical part of using 
machine learning is to have an extensive database of experimentally-defined impacts 
of mutations on stability and interactions, such as Platinum by David Ascher when 
in Cambridge [62], a database of experimentally measured effects of mutations on 
structurally defined protein-ligand complexes that was developed for mCSM-lig. 
These two structural approaches to predicting the impacts of mutations (SDM & 
mCSM) have proved complementary and more reliable than most sequence-only 
Figure 3. 
(A) Protomeric model of PyrG (CTP-Synthase) of M. leprae modelled with a quality of 4.25 (best).  
(B) Homo-8-mer of PyrG of M. leprae modelled with a quality of 4.25 (best).
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Figure 4. 
Indicates the maximum destabilising effect a mutation can induce on the stability of RNA-polymerase 
β-subunit of M. leprae (target for rifampin) measured by mCSM-stability.
methods. They also allow the application of saturation mutagenesis, facilitating  
in silico systematic analysis of mutations [63], an approach now being adopted to 
whole proteomes where every residue in each of the proteins in the proteome is 
mutated to all the other 19 amino acids and the effects of the mutations are measured 
using various methods mentioned above. In structure-guided fragment-based drug 
discovery, this provides comprehensive information on the regions of the protein 
that are less likely to lead to drug resistance and therefore can be probed by elabora-
tion of fragments/small molecules. We performed saturation mutagenesis on the 
drug targets in M. leprae for leprosy and the average or highest impact a mutation 
can induce in each residue position is depicted on the structure (Figure 4).
6.4 Active sites, cavities and fragment hotspot maps
Although comparative modelling of homologues in complex with ligands can 
often give clues about active sites, cofactor binding and substrate or other ligand 
binding sites, this is not always possible. In order to indicate putative binding 
sites in the absence of appropriate experimental data, we have exploited cavity-
defining software such as VolSite [64] for novel binding site description together 
with an alignment and comparison tool (Shaper) [65]. We have used FuzCav, a 
novel alignment-free high-throughput algorithm to compute pairwise similarities 
between protein-ligand binding sites [66] and GHECOM [67], to study the small 
pockets that often characterise protein-protein and protein-peptide interactions.
Further to the identification of cavities and pockets, it is also useful to be able to 
identify hotspots, region(s) of the binding site defined as a major contributor to the 
binding free energy, and often characterised by their ability to bind fragment-sized 
organic molecules in well-defined orientations. The usual understanding is that the 
fragment, with a mixed polar and hydrophobic character, can displace an “unhappy 
water.” We have tried to mimic this in silico by using SuperStar [68] to generate atomic 
interaction propensities on a grid. We then carry out a search with three fragments, 
each having a six-membered carbon ring, but having a donor, acceptor or a non-polar 
substituent. The resulting map is convoluted with an estimate of the depth below the 
surface, which generally appears to correlate with favourable entropic gain on water 
release on binding of a ligand [69]. The hotspot maps, computed in this way and 
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indicating donor, acceptor and lipophilic interactions correlate well with experimental 
binding sites of fragments that can be elaborated in fragment-based discovery. For the 
ligand bound structures, lower contouring can provide “warm spots” for the binding 
sites, indicating possibilities for elaborating the fragment in the binding pocket.
The models of individual molecules of the modelled proteome can be individually 
decorated with the hotspot maps. They give a good indication of the known func-
tional sites on experimentally defined structures of proteins, often demonstrating 
that a functional site comprises several hotspots involved in binding substrates and 
cofactors. They also provide a good indication of the location of allosteric sites [70].
7. Conclusion
In summary we can move from the study of individual targets to an understanding 
of the majority of targets coded by the genome. Indeed, we can build 3D structures 
for a majority of the genes, so providing a model of the “structural proteome”. 
Hotspots and cavities provide a basis for identification of the ligandability of putative 
binding sites and have been used in our group to predict pharmacophores that can be 
used in docking and virtual screening and so deorphaning of mycobacterial proteins.
To identify druggable proteins from the structural proteome, we have adopted 
a hierarchal selection process wherein chokepoint analysis is initially performed to 
identify metabolic reactions that are critical to cell survival. Gene products identi-
fied in this screen are later subjected to essentiality analysis using either flux balance 
analysis (FBA) based models or by data from the transposon saturation mutagenesis 
experiments in the literature. Genes that are essential are chosen at this stage and 
understanding of the gene expression profiles in different growth conditions is anal-
ysed. Genes whose expression is condition specific are excluded. Later for the selected 
genes, the structural information of the corresponding proteins is analysed in the 
context of prior knowledge and attempts in drug discovery, druggable pockets and 
fragment hotspots maps, small molecule bound states, non-human homologue, non-
homologous to human microbiome, cellular localization and biochemical properties 
of the proteins. Structure-guided virtual screening is performed on the selected drug 
targets with a choice of fragment and compound libraries using CCDC Gold (The 
Cambridge Crystallographic Data Centre) [71]. Best poses with good scores lead the 
experimental process of structure-guided fragment-based drug discovery.
The challenge now is to test the computational methods outlined here for 
identifying ligands and understanding the druggability of the proteome—several 
thousand gene products from the whole genome of Mtb. We can then begin to assess 
the degree to which we can de-orphan the many Mtb proteins that have until now 
not featured as targets in the worldwide efforts to combat the global challenge of TB 
to the health and well-being of human kind.
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